Inflammatory bowel disease does not alter the clinical features and the management
of acute pancreatitis: A prospective, multicentre, exact-matched cohort analysis
János Bolyai Research Scholarship(BO/00317/21) Támogató: MTA
Acute pancreatitis in inflammatory bowel disease occurs mainly as an extraintestinal
manifestation or a side effect of medications. We aimed to investigate the prognostic
factors and severity indicators of acute pancreatitis and the treatment of patients
with both diseases.We performed a matched case-control registry analysis of a multicentre,
prospective, international acute pancreatitis registry. Patients with both diseases
were matched to patients with acute pancreatitis only in a 1:3 ratio by age and gender.
Subgroup analyses were also carried out based on disease type, activity, and treatment
of inflammatory bowel disease.No difference in prognostic factors (laboratory parameters,
bedside index of severity in acute pancreatitis, imaging results) and outcomes of
acute pancreatitis (length of hospitalization, severity, and local or systemic complications)
were detected between groups. Significantly lower analgesic use was observed in the
inflammatory bowel disease population. Antibiotic use during acute pancreatitis was
significantly more common in the immunosuppressed group than in the non-immunosuppressed
group (p = 0.017). However, none of the prognostic parameters or the severity indicators
showed a significant difference between any subgroup of patients with inflammatory
bowel disease.No significant differences in the prognosis and severity of acute pancreatitis
could be detected between patients with both diseases and with pancreatitis only.
The need for different acute pancreatitis management is not justified in the coexistence
of inflammatory bowel disease, and antibiotic overuse should be avoided.
